Clinical Trial Update: Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

View source ↗

Summary

Agenus has launched an Expanded Access Program to provide Botensilimab and Balstilimab to patients before regulatory approval. The program targets multiple canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Hepatocellular Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Sarcoma

Drugs mentioned

• Balstilimab (balstilimab)
• Botensilimab (botensilimab)

Snippet

Sponsor: Agenus Inc. | Conditions: Colorectal Cancer (CRC), Pancreatic Cancer | Status: AVAILABLE